"Life Biosciences has treated the first participant in a gene therapy trial aimed at partially reprogramming aged cells. The trial targets glaucoma and NAION, conditions causing optic nerve damage. The approach uses three genes to restore youthful identity to cells, with safety monitored via a doxycycline-controlled switch."